All In MedTech

FDA Clearance Tracker · P000025-S137

MED-EL Cochlear Implant

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 23, 2026

Approved

Time to decision

32 days

Received Dec 22, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P000025-S137
Device name
MED-EL Cochlear Implant
Applicant
Med-El Corp.
Applicant location
Innsbruck
Received
Dec 22, 2025
Decided
Jan 23, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P000025

Device type

Device class
Class III

Every decision under product code MCM

FDA's approval statement

As written in FDA's record.

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which requested approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P000025/S134 Based upon the information submitted, the PMA supplement is approved.

Source documents

Other decisions for Med-El Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.